Loading..

ACADIA Pharmaceuticals Inc. (ACAD) Report Analysis

Corporate Events

Negative

Acadia Pharmaceuticals Announces Outcome of FDA...

2022-06-18 00:00:00

Acadia Pharmaceuticals Inc. announced the outcome of the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee ...

Positive

ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD) acq...

2022-06-02 00:00:00

ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD) acquired Levo Therapeutics, Inc. on June 2, 2022. Ryan A. Murr of Gibson, Dunn & Crutcher LLP acte...

Neutral

ACADIA Pharmaceuticals Inc. has filed a Shelf R...

2022-05-25 00:00:00

ACADIA Pharmaceuticals Inc. has filed a Shelf Registration in the amount of $677.453803 million. Security Name: Common Stock Securities Of...

Neutral

ACADIA Pharmaceuticals Inc. Reiterates Sales Gu...

2022-05-04 20:05:00

ACADIA Pharmaceuticals Inc. reiterated sales guidance for the full year 2022. For the period, NUPLAZID net sales guidance of $510 to $560 million.

Neutral

ACADIA Pharmaceuticals Inc. Presents at RBC Cap...

2022-05-03 20:05:00

ACADIA Pharmaceuticals Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 04:05 PM. Venue: InterContinental New Yo...

Neutral

ACADIA Pharmaceuticals Inc. - Special Call

2022-05-02 20:05:00

To review the resubmitted supplemental New Drug Application

Positive

Acadia Pharmaceuticals Announces FDA Advisory C...

2022-05-02 20:05:00

ACADIA Pharmaceuticals Inc. announced that a virtual meeting of the U.S. Food and Drug Administration'sPsychopharmacologic Drugs Advisory Comm...

Neutral

ACADIA Pharmaceuticals Inc. - Shareholder/Analyst Call

2022-04-29 21:10:00

AGM

Neutral

ACADIA Pharmaceuticals Inc., Annual General Mee...

2022-04-29 21:10:00

ACADIA Pharmaceuticals Inc., Annual General Meeting, Jun 07, 2022, at 10:00 Pacific Daylight. Agenda: To consider electing three Class III dir...

Neutral

ACADIA Pharmaceuticals Inc. to Report Q1, 2022 ...

2022-04-21 13:00:00

ACADIA Pharmaceuticals Inc. announced that they will report Q1, 2022 results After-Market on May 04, 2022

Neutral

ACADIA Pharmaceuticals Inc., Q1 2022 Earnings C...

2022-04-21 13:00:00

ACADIA Pharmaceuticals Inc., Q1 2022 Earnings Call, May 04, 2022

Positive

Acadia Pharmaceuticals Inc. Announces Top-Line ...

2022-04-18 20:05:00

ACADIA Pharmaceuticals Inc. announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating t...

Neutral

ACADIA Pharmaceuticals Inc. Presents at Bank of...

2022-03-22 05:03:00

ACADIA Pharmaceuticals Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 03:20 PM. Venue: Encore Hotel, 3121 Las Vegas ...

Neutral

RBC Capital Markets, LLC, RBC Capital Markets G...

2022-03-04 01:06:00

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New Yor...

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

ACADIA Pharmaceuticals Inc. - Special Call

2021-12-20 21:05:00

To discuss the regulatory update regarding the resubmission of the sNDA for pimavanserin for the treatment of ADP

Positive

Acadia Pharmaceuticals Announces Plan for a Res...

2021-12-20 21:05:00

Acadia Pharmaceuticals Inc. announced that it plans to resubmit its supplemental New Drug Application (sNDA) for pimavanserin for the treatmen...

Negative

Acadia Pharmaceuticals Announces Promotion of M...

2021-12-14 14:00:00

Acadia Pharmaceuticals Inc. announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective imm...

Negative

ACADIA Pharmaceuticals Inc. Announces Promotion...

2021-12-14 14:00:00

Acadia Pharmaceuticals Inc. announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective imm...

Neutral

ACADIA Pharmaceuticals Inc. - Special Call

2021-12-06 21:05:00

To discuss discuss top-line results from Lavender study of trofinetide for the treatment of Rett syndrome

Positive

Acadia Pharmaceuticals Announces Positive Top-L...

2021-12-06 21:05:00

Acadia Pharmaceuticals Inc. announced positive top-line results from the pivotal, Phase 3 Lavender™ study evaluating the efficacy and safety o...

Positive

Acadia Pharmaceuticals Inc. Announces The Lance...

2021-12-01 14:00:00

Acadia Pharmaceuticals Inc. announced that The Lancet Psychiatry published results from the Phase 2 ADVANCE study. ADVANCE was an internationa...

Neutral

ACADIA Pharmaceuticals Inc. Presents at ISG Dig...

2021-11-16 17:25:00

ACADIA Pharmaceuticals Inc. Presents at ISG Digital Business Summit, Dec-01-2021 10:25 AM. Speakers: Mike Zill, CAO and CIO.

Neutral

Information Services Group, Inc., ISG Digital B...

2021-11-16 13:32:00

Information Services Group, Inc., ISG Digital Business Summit, Dec 01, 2021 through Dec 02, 2021.

Negative

ACADIA Pharmaceuticals Inc. Revises Earnings Gu...

2021-11-08 21:05:00

ACADIA Pharmaceuticals Inc. revised earnings guidance for the full year of 2021. For the year, the company's NUPLAZID net sales guidance is na...

Positive

Acadia Pharmaceuticals Presents New Dementia-Re...

2021-11-02 13:00:00

Acadia Pharmaceuticals Inc. announced that three data presentations featuring new analyses of Medicare claims data on dementia-related psychos...

Negative

Acadia Pharmaceuticals Promotes Brendan Teehan ...

2021-11-01 20:05:00

ACADIA Pharmaceuticals Inc. announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial...

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

ACADIA Pharmaceuticals Inc. to Report Q3, 2021 ...

2021-10-27 13:09:00

ACADIA Pharmaceuticals Inc. announced that they will report Q3, 2021 results After-Market on Nov 08, 2021

Neutral

ACADIA Pharmaceuticals Inc., Q3 2021 Earnings C...

2021-10-27 13:09:00

ACADIA Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 08, 2021

Positive

Acadia Pharmaceuticals to Present Data on Pimav...

2021-10-25 13:00:00

Acadia Pharmaceuticals Inc. announced that a scientific presentation on pimavanserin for the treatment of hallucinations and delusions in pati...

Neutral

ACADIA Pharmaceuticals Inc. Presents at Morgan ...

2021-09-02 13:00:00

ACADIA Pharmaceuticals Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 11:45 AM. Venue: New Windsor, Uni...

Neutral

ACADIA Pharmaceuticals Inc. Presents at Cantor ...

2021-09-02 13:00:00

ACADIA Pharmaceuticals Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 01:20 PM. Venue: New York, United States.

Negative

Acadia Pharmaceuticals Inc. Announces Executive Changes

2021-09-01 20:05:00

Acadia Pharmaceuticals Inc. announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the comp...

Negative

Acadia Pharmaceuticals Inc. Announces Executive...

2021-09-01 20:05:00

Acadia Pharmaceuticals Inc. announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the comp...

Neutral

ACADIA Pharmaceuticals Inc. Presents at Citi’s ...

2021-09-01 18:36:00

ACADIA Pharmaceuticals Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 11:35 AM. Venue: New York, United States....

Positive

Acadia Pharmaceuticals to Conduct DAFFODILTM, A...

2021-08-31 23:11:00

Acadia Pharmaceuticals will be conducting DAFFODILTM, a clinical study of trofinetide in approximately 10 girls with diagnosed Rett syndrome, ...

Neutral

ACADIA Pharmaceuticals Inc. Presents at Canacco...

2021-08-05 20:05:00

ACADIA Pharmaceuticals Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-12-2021 03:00 PM. Speakers: Elena H. Ridloff, Exe...

Positive

Neuren Pharmaceuticals Announces Its Us Partner...

2021-08-04 22:14:00

Neuren Pharmaceuticals announced that its US partner for trofinetide, Acadia Pharmaceuticals, has successfully completed enrolment in the LAVE...

Negative

ACADIA Pharmaceuticals Inc. Revises Sales Guida...

2021-08-04 20:16:00

ACADIA Pharmaceuticals Inc. revised sales guidance for the year 2021. For the year, the company's NUPLAZID net sales guidance is decreased to ...

Positive

ACADIA Pharmaceuticals Inc. Announces the New E...

2021-07-21 21:05:00

Acadia Pharmaceuticals Inc. announced that the New England Journal of Medicine published results from the Phase 3 HARMONY study, an internatio...

Neutral

ACADIA Pharmaceuticals Inc. to Report Q2, 2021 ...

2021-07-21 13:00:00

ACADIA Pharmaceuticals Inc. announced that they will report Q2, 2021 results After-Market on Aug 04, 2021

Neutral

ACADIA Pharmaceuticals Inc., Q2 2021 Earnings C...

2021-07-21 13:00:00

ACADIA Pharmaceuticals Inc., Q2 2021 Earnings Call, Aug 04, 2021

Negative

Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for Nuplazid® (Pimavanserin) for the Treatment of Alzheimer’S Disease Psychosis

2022-06-18 00:00:00

Acadia Pharmaceuticals Inc. announced the outcome of the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The PDAC voted 9 to 3 that the evidence presented does not support a conclusion that pimavanserin is effective for the treatment of hallucinations and delusions in the ADP population. The FDA asked the PDAC for advice and recommendations regarding the evidence that pimavanserin is effective for the treatment of hallucinations and delusions associated with ADP. The FDA is not bound by the PDAC’s recommendations, but takes its advice into consideration when making decisions on drug applications. The FDA’s target action date is August 4, 2022. NUPLAZID was approved in the U.S. in 2016 as the first and only treatment for hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). The totality of clinical trial, post-marketing and observational real-world evidence continue to support a positive benefit-risk profile for NUPLAZID for the treatment of hallucinations and delusions associated with PDP.

Positive

ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD) acquired Levo Therapeutics, Inc.

2022-06-02 00:00:00

ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD) acquired Levo Therapeutics, Inc. on June 2, 2022. Ryan A. Murr of Gibson, Dunn & Crutcher LLP acted as legal advisor to Levo Therapeutics. ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD) completed the acquisition of Levo Therapeutics, Inc. on June 2, 2022.

Neutral

ACADIA Pharmaceuticals Inc. has filed a Shelf Registration in the amount of $677.453803 million.

2022-05-25 00:00:00

ACADIA Pharmaceuticals Inc. has filed a Shelf Registration in the amount of $677.453803 million. Security Name: Common Stock Securities Offered: 42,393,855

Neutral

ACADIA Pharmaceuticals Inc. Reiterates Sales Guidance for the Full Year 2022

2022-05-04 20:05:00

ACADIA Pharmaceuticals Inc. reiterated sales guidance for the full year 2022. For the period, NUPLAZID net sales guidance of $510 to $560 million.

Neutral

ACADIA Pharmaceuticals Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 04:05 PM

2022-05-03 20:05:00

ACADIA Pharmaceuticals Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 04:05 PM. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.

Neutral

ACADIA Pharmaceuticals Inc. - Special Call

2022-05-02 20:05:00

To review the resubmitted supplemental New Drug Application

Positive

Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for Nuplazid

2022-05-02 20:05:00

ACADIA Pharmaceuticals Inc. announced that a virtual meeting of the U.S. Food and Drug Administration'sPsychopharmacologic Drugs Advisory Committee to review the resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) has been scheduled for June 17, 2022. The target action date for the application is August 4, 2022.

Neutral

ACADIA Pharmaceuticals Inc. - Shareholder/Analyst Call

2022-04-29 21:10:00

AGM

Neutral

ACADIA Pharmaceuticals Inc., Annual General Meeting, Jun 07, 2022

2022-04-29 21:10:00

ACADIA Pharmaceuticals Inc., Annual General Meeting, Jun 07, 2022, at 10:00 Pacific Daylight. Agenda: To consider electing three Class III directors named herein to hold office until the Company's 2025 Annual Meeting of Stockholders; to consider approving an amendment to the Company's 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,000,000 shares; to consider approving the compensation of the Company's named executive officers; to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022; and to conduct any other business properly brought before the meeting.

Neutral

ACADIA Pharmaceuticals Inc. to Report Q1, 2022 Results on May 04, 2022

2022-04-21 13:00:00

ACADIA Pharmaceuticals Inc. announced that they will report Q1, 2022 results After-Market on May 04, 2022

Neutral

ACADIA Pharmaceuticals Inc., Q1 2022 Earnings Call, May 04, 2022

2022-04-21 13:00:00

ACADIA Pharmaceuticals Inc., Q1 2022 Earnings Call, May 04, 2022

Positive

Acadia Pharmaceuticals Inc. Announces Top-Line Results from Phase 2 Study Evaluating Acp-044 for the Treatment of Acute Postoperative Pain

2022-04-18 20:05:00

ACADIA Pharmaceuticals Inc. announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. The primary endpoint, a comparison of cumulative pain intensity scores over 24 hours between the ACP-044 1600 mg once daily, ACP-044 400 mg four times daily and placebo treatment arms, was not met. A trend favoring the ACP-044 400 mg once every six hours treatment group was observed on the primary endpoint, a difference of -10.5 points compared to placebo (p = 0.1683; effect size = 0.219). These numerical trends were consistently better than placebo, but not statistically significant, at 48 hours and 72 hours. Most adverse events were mild-to-moderate and there were no serious adverse events related to ACP-044. Fewer patients discontinued treatment in the ACP-044 arms than in the placebo group. Acadia is currently evaluating ACP-044 in an ongoing study in osteoarthritis, a model of chronic pain, which is expected to complete in the first half of 2023.

Neutral

ACADIA Pharmaceuticals Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 03:20 PM

2022-03-22 05:03:00

ACADIA Pharmaceuticals Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 03:20 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Stephen R. Davis, CEO & Director.

Neutral

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022

2022-03-04 01:06:00

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

ACADIA Pharmaceuticals Inc. - Special Call

2021-12-20 21:05:00

To discuss the regulatory update regarding the resubmission of the sNDA for pimavanserin for the treatment of ADP

Positive

Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)

2021-12-20 21:05:00

Acadia Pharmaceuticals Inc. announced that it plans to resubmit its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia focused on Alzheimer’s disease psychosis (ADP). Resubmission of the sNDA to the U.S. Food and Drug Administration (FDA) is planned for the first quarter of 2022. The resubmission is intended to demonstrate pimavanserin’s clinically meaningful benefit in ADP patients, without worsening of cognition or motor function in this elderly population. The resubmission will include data from two positive, placebo-controlled studies that prospectively met their primary endpoints: the pivotal Phase 3 HARMONY study1 and the -019 study2. Additional analyses from HARMONY and -019 will also be provided that validate the primary conclusions from each study and address the concerns raised in the FDA’s complete response letter.

Negative

Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer

2021-12-14 14:00:00

Acadia Pharmaceuticals Inc. announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective immediately. Mr. Schneyer has served as the company’s interim CFO since September 2021, while retaining his responsibilities as Acadia’s head of business development and Chief Business Officer. Mr. Schneyer’s responsibilities as CFO will include the functional areas of finance, accounting, investor relations, and business development. Mr. Schneyer will continue to report to Steve Davis, Chief Executive Officer, and will remain a member of the company’s Executive Management Committee.

Negative

ACADIA Pharmaceuticals Inc. Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer

2021-12-14 14:00:00

Acadia Pharmaceuticals Inc. announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective immediately. Mr. Schneyer has served as the company’s interim CFO since September 2021, while retaining his responsibilities as Acadia’s head of business development and Chief Business Officer. Mr. Schneyer’s responsibilities as CFO will include the functional areas of finance, accounting, investor relations, and business development. Mr. Schneyer will continue to report to Steve Davis, Chief Executive Officer, and will remain a member of the company’s Executive Management Committee.

Neutral

ACADIA Pharmaceuticals Inc. - Special Call

2021-12-06 21:05:00

To discuss discuss top-line results from Lavender study of trofinetide for the treatment of Rett syndrome

Positive

Acadia Pharmaceuticals Announces Positive Top-Line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome

2021-12-06 21:05:00

Acadia Pharmaceuticals Inc. announced positive top-line results from the pivotal, Phase 3 Lavender™ study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome. The 12-week placebo-controlled study demonstrated a statistically significant improvement over placebo for both co-primary endpoints. On the Rett Syndrome Behaviour Questionnaire (RSBQ), change from baseline to week 12 was -5.1 vs. -1.7 (p=0.0175; effect size=0.37). The Clinical Global Impression–Improvement (CGI-I) score at week 12 was 3.5 vs. 3.8 (p=0.0030; effect size=0.47). The RSBQ is a caregiver assessment of the core symptoms of Rett syndrome and the CGI-I is a global physician assessment of worsening or improving of Rett syndrome. Additionally, trofinetide demonstrated a statistically significant separation over placebo on the key secondary endpoint, the Communication and Symbolic Behavior Scales Developmental Profile™ Infant-Toddler Checklist–Social composite score (CSBS-DP-IT–Social) change from baseline to week 12 was -0.1 vs. -1.1 (p=0.0064; effect size=0.43). Study treatment discontinuation rates related to treatment emergent adverse events (TEAEs) were 17.2% in the trofinetide group as compared to 2.1% in the placebo group. The most common adverse events were diarrhea (80.6% with trofinetide vs. 19.1% with placebo), of which 97.3% in the trofinetide arm were characterized as mild-to-moderate, and vomiting (26.9% with trofinetide vs. 9.6% with placebo), of which 96% in the trofinetide arm were characterized as mild-to-moderate. Serious adverse events were observed in 3.2% of study participants in both the trofinetide and placebo groups. Patients completing the Lavender study had the opportunity to continue to receive trofinetide in the open-label Lilac and Lilac-2 extension studies. More than 95% of participants who completed the Lavender study elected to roll-over to the Lilac open-label extension study. The results from this study will be submitted for presentation at upcoming medical meetings. Acadia is preparing for a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) in the first quarter of 2022 and plans to submit a New Drug Application (NDA) around mid-year 2022. Trofinetide has been granted Fast Track Status and Orphan Drug Designation for Rett syndrome. Trofinetide has also been granted Rare Pediatric Disease (RPD) designation by the FDA. An NDA with Orphan Drug Designation is eligible for priority review. With an RPD NDA would expect to be awarded a Priority Review Voucher if approved, subject to final determination by the FDA. In 2018, Acadia entered into an exclusive license agreement with Neuren Pharmaceuticals Limited for the development and commercialization of trofinetide for Rett syndrome and other indications in North America.

Positive

Acadia Pharmaceuticals Inc. Announces The Lancet Psychiatry Published Results from the Phase 2 ADVANCE study

2021-12-01 14:00:00

Acadia Pharmaceuticals Inc. announced that The Lancet Psychiatry published results from the Phase 2 ADVANCE study. ADVANCE was an international, 26-week, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of adjunctive pimavanserin treatment in outpatients with moderate-to-severe predominant negative symptoms of schizophrenia who had achieved control of positive symptoms with their ongoing antipsychotic treatment. ADVANCE met its primary endpoint, with significant improvement observed with pimavanserin for the change from baseline to week 26 on the Negative Symptoms Assessment-16 (NSA-16) total score, compared with placebo (-10.4 vs. -8.5; p=0.043). In a post hoc analysis, greater improvement in the NSA-16 total score compared to placebo was observed in the 53.8% of patients (n=107) who received the highest pimavanserin dose of 34 mg (-11.6 vs. -8.5; unadjusted p=0.0065). In the study, pimavanserin was well-tolerated with high completion rates of approximately 86% in both the pimavanserin and placebo treatment groups through 26 weeks and similar rates of adverse events between pimavanserin (39.8%) and placebo (35.1%). Additionally, no clinically significant differences in vital signs, weight, metabolic syndrome or extrapyramidal symptoms were observed in the pimavanserin group compared to placebo. Serious adverse events were reported in 2.0% of patients on pimavanserin and 0.5% of patients on placebo and discontinuations due to adverse events were also low, 5.0% for pimavanserin and 3.0% for placebo.

Neutral

ACADIA Pharmaceuticals Inc. Presents at ISG Digital Business Summit, Dec-01-2021 10:25 AM

2021-11-16 17:25:00

ACADIA Pharmaceuticals Inc. Presents at ISG Digital Business Summit, Dec-01-2021 10:25 AM. Speakers: Mike Zill, CAO and CIO.

Neutral

Information Services Group, Inc., ISG Digital Business Summit, Dec 01, 2021 through Dec 02, 2021

2021-11-16 13:32:00

Information Services Group, Inc., ISG Digital Business Summit, Dec 01, 2021 through Dec 02, 2021.

Negative

ACADIA Pharmaceuticals Inc. Revises Earnings Guidance for the Full Year of 2021

2021-11-08 21:05:00

ACADIA Pharmaceuticals Inc. revised earnings guidance for the full year of 2021. For the year, the company's NUPLAZID net sales guidance is narrowed to $480 to $500 million from the previous range of $480 to $515 million.

Positive

Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021

2021-11-02 13:00:00

Acadia Pharmaceuticals Inc. announced that three data presentations featuring new analyses of Medicare claims data on dementia-related psychosis (DRP) outcomes were presented at Psych Congress 2021, held virtually and in-person October 29-November 1, 2021 in San Antonio, TX. The presentations demonstrate the suboptimal outcomes associated with the off-label use of currently available atypical antipsychotic treatments in managing dementia-related hallucinations and delusions, along with the related cost burdens. Details of the posters presented are as follows: Poster:Treatment Emergent Adverse Events and Associated Adverse Event-Specific Per-Patient-Per-Year Costs: Analysis of Medicare Beneficiaries Treated with Off-Label Atypical Antipsychotics for Dementia-Related Psychosis: Data from a Medicare claims analysis of 23,267 patients with dementia-related psychosis initiating atypical antipsychotic monotherapy from January 2014 through December 2017 showed that over 70% had one or more adverse events (AEs) within one year, with 64% experiencing dyslipidemia, 50% experiencing peripheral vascular disease (PVD) and 40% experiencing cerebrovascular adverse events (CVAEs) such as stroke and transient ischemic attacks. Median per-patient-per-year (PPPY) costs of hyperlipidemia, PVD, and CVAE were $5,565, $227 and $3,682, respectively. Poster: Incremental Cost of Treatment Emergent Falls/Fractures, Stroke and Cerebrovascular Adverse Events Among Patients on Atypical Antipsychotics: Analysis of Medicare Patients with Dementia-Related Psychosis: A Medicare claims analysis of 23,267 treated DRP patients showed approximately one in five patients experienced falls/fractures or stroke (23% and 17%, respectively) while nearly two in five patients (38%) experienced other CVAEs including stroke or transient ischemic attacks. The incremental median annual total costs were significantly higher among patients with AEs compared to those without AEs after treatment initiation for falls or fractures ($70,932 vs. $44,221), CVAE ($68,308 vs. $40,061) and stroke ($74,234 vs. $45,999). These results suggest that patients experiencing these AEs had over 60% higher total annual costs compared with those who did not experience the AEs (p<0.05). Poster: Incremental Cost of Suboptimal Treatment Outcomes Among Patients with Dementia-Related Psychosis: Analysis of Medicare Beneficiaries: An analysis of Medicare claims of 35,100 atypical antipsychotic new start patients with DRP found that nearly two out of three patients experienced at least one suboptimal treatment outcomes (e.g., treatment augmentation, discontinuation or psychosis-specific hospitalizations). Median annual total costs were nearly two times higher ($29,898) among patients with suboptimal outcomes compared with patients who did not experience suboptimal outcomes ($14,158; p<0.05). Total costs also doubled or quadrupled with the occurrence of two or more or four or more suboptimal outcome-events, respectively. Approximately 8 million people in the United States are living with dementia, a condition with a core feature of declining cognition (changes in memory, decision-making abilities, language, etc.) resulting in functional impairment. Dementia is a manifestation of an underlying condition which is often progressive and neurodegenerative in nature.1 In addition to cognitive decline, dementing illnesses almost universally lead to neuropsychiatric symptoms, which may include hallucinations, delusions, and changes in behavior. It is estimated that 2.4 million Americans (or 30% of people with dementia) experience dementia-related hallucinations and delusions. These symptoms may be frequent and severe and may recur over time. A hallucination is defined as a perception-like experience that occurs without an external stimulus and is sensory (seen, heard, felt, tasted, sensed) in nature. A delusion is defined as a false, fixed belief that is resolutely held despite evidence to the contrary. Dementia-related psychosis occurs in many types of dementia, including Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease dementia, vascular dementia, and frontotemporal dementia. Serious consequences have been associated with psychosis in patients with dementia, such as repeated hospital admissions, increased likelihood of nursing home placement, faster progression of dementia, and increased risk of morbidity and mortality.

Negative

Acadia Pharmaceuticals Promotes Brendan Teehan to Executive Vice President, Chief Operating Officer and Head of Commercial

2021-11-01 20:05:00

ACADIA Pharmaceuticals Inc. announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective immediately. Mr. Teehan, previously Senior Vice President, Chief Insights and Analytics Officer, will continue to report to Steve Davis, Chief Executive Officer and continue to serve as a member of the company’s Executive Management Committee. He will assume responsibility for all sales and marketing functions, in addition to his current responsibilities leading commercial strategy, operations, patient services, and market access and reimbursement. Since joining Acadia, Mr. Teehan has built the company’s insights, analytics and operations department, and has led the company’s annual brand and business planning processes. Operationally, he oversees Acadia’s principal decision making bodies that set the company’s strategic priorities across the commercial, clinical, operations and business development functions. Brendan Teehan joined Acadia in July 2018 and has more than 25 years of global experience in the healthcare industry. He has held roles of increasing responsibility at biopharmaceutical companies, including Johnson & Johnson and Amgen, and over the course of his career he has led field sales, operations and marketing teams in the U.S. and Europe and successfully launched small and large molecule products. Mr. Teehan began his career with Johnson & Johnson, where he held a variety of commercial roles across numerous therapeutic categories including oncology, immunology, inflammation, transplantation, chronic obstructive pulmonary disease and asthma. Mr. Teehan joined Acadia from TESARO Inc., where he served as vice president, building and leading the company’s first provider support function designed to help oncologists optimize patient care. Mr. Teehan received his MBA from Carnegie Mellon University, Tepper School of Business and his Bachelor of Arts degree in Government and International Relations from the University of Notre Dame. Charmaine Lykins, Senior Vice President, Global Product Planning and Chief Marketing Officer, and Amanda Morgan, Senior Vice President, Chief Revenue and Customer Officer, will be leaving the organization to pursue new opportunities after a brief transition period.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

ACADIA Pharmaceuticals Inc. to Report Q3, 2021 Results on Nov 08, 2021

2021-10-27 13:09:00

ACADIA Pharmaceuticals Inc. announced that they will report Q3, 2021 results After-Market on Nov 08, 2021

Neutral

ACADIA Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 08, 2021

2021-10-27 13:09:00

ACADIA Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 08, 2021

Positive

Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

2021-10-25 13:00:00

Acadia Pharmaceuticals Inc. announced that a scientific presentation on pimavanserin for the treatment of hallucinations and delusions in patients with Parkinson’s disease dementia will be shared at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held virtually and in-person November 9-12, 2021 in Boston, MA. CTAD Accepted Presentation: Poster Presentation (#LRP2): Pimavanserin treatment of hallucinations and delusions in patients with Parkinson’s disease dementia: post-hoc analysis of the HARMONY trial, available to view on November 9, 2021. Presenting author: Daniel Weintraub, M.D., Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. About Pimavanserin Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID®. NUPLAZID is not approved for dementia-related psychosis. In addition, Acadia is developing pimavanserin in other neuropsychiatric conditions. Indication NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis. Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported. Warnings and Precautions: QT Interval Prolongation NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval. Adverse Reactions: Thecommon adverse reactions(=2% for NUPLAZID and greater than placebo) wereperipheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%). Drug Interactions: Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily. Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

Neutral

ACADIA Pharmaceuticals Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 11:45 AM

2021-09-02 13:00:00

ACADIA Pharmaceuticals Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 11:45 AM. Venue: New Windsor, United States.

Neutral

ACADIA Pharmaceuticals Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 01:20 PM

2021-09-02 13:00:00

ACADIA Pharmaceuticals Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 01:20 PM. Venue: New York, United States.

Negative

Acadia Pharmaceuticals Inc. Announces Executive Changes

2021-09-01 20:05:00

Acadia Pharmaceuticals Inc. announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the company effective September 10, 2021 to join another biopharmaceutical company. Mark Schneyer, Senior Vice President, Business Development and Chief Business Officer, will serve as Acadia’s interim Chief Financial Officer. The company is conducting a formal search for a new CFO.

Negative

Acadia Pharmaceuticals Inc. Announces Executive Leadership Change, Effective September 10, 2021

2021-09-01 20:05:00

Acadia Pharmaceuticals Inc. announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the company effective September 10, 2021 to join another biopharmaceutical company. Mark Schneyer, Senior Vice President, Business Development and Chief Business Officer, will serve as Acadia’s interim Chief Financial Officer. The company is conducting a formal search for a new CFO.

Neutral

ACADIA Pharmaceuticals Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 11:35 AM

2021-09-01 18:36:00

ACADIA Pharmaceuticals Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 11:35 AM. Venue: New York, United States. Speakers: Elena H. Ridloff, Executive VP & CFO, Steve Davis, CEO.

Positive

Acadia Pharmaceuticals to Conduct DAFFODILTM, A Clinical Study of Trofinetide

2021-08-31 23:11:00

Acadia Pharmaceuticals will be conducting DAFFODILTM, a clinical study of trofinetide in approximately 10 girls with diagnosed Rett syndrome, aged 2 to 5 years. DAFFODIL will be a 12-week, multicenter, open-label safety, tolerability and pharmacokinetics study in this younger age group, followed by a possible open-label extension for up to an additional 21 months.

Neutral

ACADIA Pharmaceuticals Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-12-2021 03:00 PM

2021-08-05 20:05:00

ACADIA Pharmaceuticals Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-12-2021 03:00 PM. Speakers: Elena H. Ridloff, Executive VP & CFO, Mark C. Johnson, Vice President of Investor Relations, Steve Davis, Chief Executive Officer.

Positive

Neuren Pharmaceuticals Announces Its Us Partner for Trofinetide, Acadia Pharmaceuticals, Successfully Completes Enrolment in the Lavender Phase 3 Trial of Trofinetide in Rett Syndrome

2021-08-04 22:14:00

Neuren Pharmaceuticals announced that its US partner for trofinetide, Acadia Pharmaceuticals, has successfully completed enrolment in the LAVENDER Phase 3 trial of trofinetide in Rett syndrome, remaining on track for top-line results in Fourth Quarter 2021. LAVENDER is a randomised, double-blind, placebo-controlled Phase 3 trialtesting treatment of approximately 180 patients for 12 weeks with trofinetide or placebo. Rett syndrome is a debilitating neurodevelopmental disorder estimated to affect between 1 in 10,000 and 1 in 15,000 females worldwide. A range of severe impairments emerge in infancy, affecting nearly every aspect of the child's life: their ability to speak, walk, eat, and even breathe. There are currently no medicines approved for Rett syndrome. The trofinetide program has Fast Track, Orphan Drug and Rare Pediatric Disease designations from the US Food and Drug Administration (FDA). The development and commercialisation of trofinetide in North America is fully funded by Acadia. Neuren is eligible to receive potential milestone payments of up to USD 455 million, plus tiered escalating double-digit percentage royalties on net sales of trofinetide in North America, plus one third of the market value of a Rare Pediatric Disease Priority Review Voucher if awarded by the FDA upon approval of a New Drug Application for trofinetide. Further, Neuren has free and full access to all data for use in countries outside North America.

Negative

ACADIA Pharmaceuticals Inc. Revises Sales Guidance for the Year 2021

2021-08-04 20:16:00

ACADIA Pharmaceuticals Inc. revised sales guidance for the year 2021. For the year, the company's NUPLAZID net sales guidance is decreased to $480 to $515 million from the previous range of $510 to $550 million as a result of the continued impact of the pandemic with fewer Parkinson's disease patient office visits and lower occupancy rates at long-term care facilities, as well as a revised gross-to-net expectation of approximately 20% compared to prior expectation of high teens.

Positive

ACADIA Pharmaceuticals Inc. Announces the New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis

2021-07-21 21:05:00

Acadia Pharmaceuticals Inc. announced that the New England Journal of Medicine published results from the Phase 3 HARMONY study, an international, double-blind, placebo-controlled relapse prevention trial in 392 patients evaluating pimavanserin as an investigational treatment in patients with hallucinations and delusions associated with dementia-related psychosis (DRP). The study included patients across five subgroups of dementia: Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson’s disease dementia, and vascular dementia.The HARMONY study was stopped early due to positive efficacy at the pre-planned interim analysis upon recommendation of the trial’s independent data safety monitoring board. HARMONY met its primary endpoint by significantly reducing the risk of relapse of psychosis by 2.8 fold compared to placebo in the double-blind period (hazard ratio (HR)=0.35, two-sided p=0.005; one-sided p=0.0023). The study also met its secondary endpoint by significantly reducing the time to trial discontinuation for any reason (HR=0.45, two-sided p=0.005; one-sided p=0.0024). The data from the HARMONY study demonstrates that patients with DRP who had responded to pimavanserin had a significantly lower risk of relapse of psychosis with continuation of pimavanserin compared to placebo up to 26 weeks. Pimavanserin was well-tolerated over the nine-month study duration. In a pre-specified analysis, pimavanserin was not associated with a decline in cognition as measured by Mini-Mental State Examination (MMSE) or the onset or worsening of motor symptoms as measured by Extrapyramidal Symptom Rating Scale A (ESRS-A). HARMONY was a Phase 3 study designed to evaluate the efficacy and safety of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis. The study included patients with Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson’s disease dementia, and vascular dementia. A total of 392 patients were enrolled in the study, with a mean age of 74.5 years and a mean MMSE score of 16.7. The primary endpoint in the study was time from randomization to relapse of psychosis in the double-blind period as represented by the Kaplan-Meier curve and the hazard ratio. The HARMONY study included a 12-week, open-label stabilization period during which patients with dementia-related psychosis began treatment with pimavanserin 34 mg once daily. In the open-label period, a majority (61.8%) of eligible subjects (n=351) met the sustained treatment response criteria at Week 8 and Week 12 and entered the double-blind period. Following the open-label period, patients who met pre-specified criteria for sustained treatment response were then randomized into the double-blind period of the study to continue their pimavanserin dose or switched to placebo and followed for up to 26 weeks or until a relapse of psychosis occurred. Pimavanserin met its primary endpoint and was stopped at the pre-planned interim analysis for positive efficacy, demonstrating that pimavanserin significantly reduced the risk of relapse of psychosis by 2.8 fold compared to placebo (HR=0.35, p=0.005). In the double-blind period, similar, low rates of adverse events were observed, 43 (41.0%) patients on pimavanserin (n=105) and 41 (36.6%) patients on placebo (n=112). Discontinuations in the double-blind period due to adverse events were low, 2.9% for pimavanserin and 3.6% for placebo. Rates of serious adverse events were also low, 4.8% in the pimavanserin group and 3.6% in the placebo group. One death was reported in the open-label period and one death was reported in the pimavanserin group during the double-blind period. Investigators determined that neither death was related to the study drug. Dementia-Related Psychosis: Approximately 8 million people in the United States are living with dementia, a condition with a core feature of declining cognition (changes in memory, decision-making abilities, language, etc.) resulting in functional impairment. Dementia is a manifestation of an underlying condition which is often progressive and neurodegenerative in nature. In addition to cognitive decline, dementing illnesses almost universally lead to neuropsychiatric symptoms, which may include hallucinations, delusions, and changes in behavior.It is estimated that 2.4 million Americans (or 30% of people with dementia) experience dementia-related hallucinations and delusions. These symptoms may be frequent and severe and may recur over time. A hallucination is defined as a perception-like experience that occurs without an external stimulus and is sensory (seen, heard, felt, tasted, sensed) in nature. A delusion is defined as a false, fixed belief that is resolutely held despite evidence to the contrary. Dementia-related psychosis occurs in many types of dementia, including Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease dementia, vascular dementia, and frontotemporal dementia. Serious consequences have been associated with psychosis in patients with dementia, such as repeated hospital admissions, increased likelihood of nursing home placement, faster progression of dementia, and increased risk of morbidity and mortality. Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID. NUPLAZID is not approved for dementia-related psychosis. In addition, Acadia is developing pimavanserin in other neuropsychiatric conditions.

Neutral

ACADIA Pharmaceuticals Inc. to Report Q2, 2021 Results on Aug 04, 2021

2021-07-21 13:00:00

ACADIA Pharmaceuticals Inc. announced that they will report Q2, 2021 results After-Market on Aug 04, 2021

Neutral

ACADIA Pharmaceuticals Inc., Q2 2021 Earnings Call, Aug 04, 2021

2021-07-21 13:00:00

ACADIA Pharmaceuticals Inc., Q2 2021 Earnings Call, Aug 04, 2021

Fundamental Summary

Looking at ACADIA Pharmaceuticals's financials of Q1 reflected unimpressive, mediocre results. It is highly likely that the company will be mostly tethered to market performance and sector movements for the near term. As such, ACADIA Pharmaceuticals received an overall score of 61 and a HOLD recommendation.

ACADIA Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 115.47 million compared to USD 106.55 million a year ago. Net loss was USD 113.06 million compared to USD 66.45 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 0.42 a year ago.

Business Description

ACADIA Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It’s pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer’s disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer’s. ACADIA Pharmaceuticals was founded in 1993 and is headquartered in San Diego, California.

Sector Overview

ACADIA Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. ACADIA Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 624.3 -10.8% 65
Liabilities 179.5 12.7% 83
Price to Book 6.1 -12.0% 55
Cash & Equivalents 204.9 39.0% 91
Equity 444.8 -17.8% 55
EBITDA -205.1 -29.6% 49
Total Revenues 493.1 1.8% 72
Parameter Value Change Score
Return on Equity -41.8 -45.4% 80
Net Cashflow -99.6 44.2% 61
Capital Expenditure -0.0 95.9% 98
Asset Turnover 0.7 9.5% 80
Free Cashflow -0.9 -11.7% 57

* All values are TTM

The below chart reflects ACADIA Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While ACADIA Pharmaceuticals's peer average final assessment score stands on 62.0, ACADIA Pharmaceuticals's score is 61.

  •  ACAD
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 25 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. ACADIA Pharmaceuticals's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), ACADIA Pharmaceuticals's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.

Bearish 37
Close Price 14.0
52W Low 13.01
52W High 27.5
5D MA 14.35
50D MA 17.62
200D MA 20.74
MACD -0.93
RSI 33.7
STOCH 15.23

Balance Sheet Analysis

ACADIA Pharmaceuticals appears likely to maintain its strong balance sheet metrics and momentum going forward. ACADIA Pharmaceuticals reported a positive trendline in their cash and cash equivalents metrics. Specifically, they reported that cash and cash equivalents were 204.9, representing 39.0% change from the last report. This impressive growth, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Consequently, their cash and cash equivalents movement received a grade of 91. Also, ACADIA Pharmaceuticals has done an excellent job managing its liabilities. ACADIA Pharmaceuticals's liabilities stood at 179.5 in the current filing, which represents a 12.7% change from the previous report. These liabilities changes appear balanced compared to their peers and project the message that management is capable and focused on balancing asset growth, resource allocation, and growing liabilities. These results statistically lead to positive movement in stock prices, so we rated its liabilities movement component 83. On the other hand, Book Value Factors, jumped out as looking rather underwhelming. ACADIA Pharmaceuticals's price to book ratio (P/B) was reported as 6.1 and represents -12.0% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. The company's book value factors were lackluster and showed that management hasn't figured out how to overperform expectations. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 55. Therefore, their balance sheet earned a grade of 63.

Parameter Value Change Score
Assets 624.3 -10.8% 65
Liabilities 179.5 12.7% 83
Price to Book 6.1 -12.0% 55
Cash & Equivalents 204.9 39.0% 91
Equity 444.8 -17.8% 55
* All values are TTM

The below chart describes ACADIA Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While ACADIA Pharmaceuticals received a balance sheet score of 63, the average of its peers stands on 61.0.

  •  ACAD
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 25 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

A deep look into ACADIA Pharmaceuticals's income statement metrics showed some disappointing metrics. The most troubling factors we're looking at are the EBITDA and Revenue Efficiency . ACADIA Pharmaceuticals's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -205.1, which represents a -29.6% change from the last period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. Their EBITDA metrics are even more problematic when compared to their peers. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 49. Also, ACADIA Pharmaceuticals's revenue efficiency metrics look especially concerning this period, highlighting issues management is having controlling and reducing expenses while increasing earnings. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Consequently, their revenue efficiency received a grade of 72. On the other hand, Return Factors, jumped out as looking rather positive. ACADIA Pharmaceuticals's reported return on equity (ROE) ratio was -41.8, representing a change of -45.4%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 80. The companie's income statement, therefore, earned a score of 58.

Parameter Value Change Score
EBITDA -205.1 -29.6% 49
Total Revenues 493.1 1.8% 72
Return on Equity -41.8 -45.4% 80
* All values are TTM

The below chart describes ACADIA Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While ACADIA Pharmaceuticals received a income statement score of 58 , the average of its peers stands on 66.0.

  •  ACAD
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 25 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Overall, ACADIA Pharmaceuticals's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. ACADIA Pharmaceuticals's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -0.0, which represents a 95.9% change from the last period. This performance is all the more impressive relative to their peers and competitors. Consequently, their CapEx movement received a grade of 98. Also, ACADIA Pharmaceuticals's published asset turnover numbers were encouraging and reflected management's balanced change strategy. ACADIA Pharmaceuticals recorded asset turnover of 0.7, which represents a 9.5% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. The company's asset turnover movement, therefore, received a grade of 80. On the other hand, Free Cash flow, jumped out as looking problematic. Free cash flow numbers published by ACADIA Pharmaceuticals were -0.9, which was a -11.7% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. their free cash flow situation appears to be much weaker than their peers. Management needs to do a better job balancing cash flow, asset growth, and resources allocations in general. Disappointing results in free cash flow often lead to negative pressure in stock prices, so we rated their free cash flow with a score of 57. Consequently, the company's cash flow earned a score of 72.

Parameter Value Change Score
Net Cashflow -99.6 44.2% 61
Capital Expenditure -0.0 95.9% 98
Asset Turnover 0.7 9.5% 80
Free Cashflow -0.9 -11.7% 57
* All values are TTM

The below chart describes ACADIA Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While ACADIA Pharmaceuticals received a cash flow score of 72, the average of its peers stands on 70.0.

  •  ACAD
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 25 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.